NURLF (Neural Therapeutics) Cash Flow for Lease Financing: $0.00 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Cash Flow for Lease Financing?

Neural Therapeutics NURLF Cash Flow for Lease Financing is $0.00 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's Cash Flow for Lease Financing for the three months ended in Jan. 2026 was $0.00 Mil. Neural Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jan. 2026 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Oct. 2025 ), Neural Therapeutics's Cash Flow for Lease Financing remained the same in Jan. 2026 ($0.00 Mil).

Neural Therapeutics Cash Flow for Lease Financing Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Cash Flow for Lease Financing Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cash Flow for Lease Financing
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neural Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Lease Financing of $0.00 Mil mean?
Neural Therapeutics (NURLF) has a Cash Flow for Lease Financing of $0.00 Mil as of Jan. 2026. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Neural Therapeutics and its competitors.
Is Neural Therapeutics' Cash Flow for Lease Financing too high?
Neural Therapeutics' current Cash Flow for Lease Financing is $0.00 Mil.
How does Neural Therapeutics' Cash Flow for Lease Financing compare to VRTX and REGN?
Neural Therapeutics' Cash Flow for Lease Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Lease Financing for a Biotechnology company?
A good Cash Flow for Lease Financing depends on the Biotechnology industry context. However, Cash Flow for Lease Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Lease Financing mean?
A high Cash Flow for Lease Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current Cash Flow for Lease Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current Cash Flow for Lease Financing of $0.00 Mil. The current Cash Flow for Lease Financing is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Lease Financing calculated?
Cash Flow for Lease Financing is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current Cash Flow for Lease Financing is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:GermanyNURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.